匹伐他汀联合利拉鲁肽治疗2型糖尿病合并非酒精性脂肪肝的疗效  

Efficacy of pitavastatin combined with liraglutide in the treatment of type 2 diabetes mellitus combined with non-alcoholic fatty liver disease

作　　者：张玉峰 曾祥洪 胡群 ZHANG Yufeng;ZENG Xianghong;HU Qun(Department of Endocrine and Metabolic Diseases,XinSteel Center Hospital,Jiangxi Province,Xinyu 338000,China)

机构地区：[1]新钢中心医院内分泌代谢性疾病科,江西省新余市338000

出　　处：《临床合理用药杂志》2023年第34期16-19,共4页Chinese Journal of Clinical Rational Drug Use

基　　金：新余市科技计划项目(20223090946)。

摘　　要：目的 观察匹伐他汀联合利拉鲁肽治疗2型糖尿病(T2DM)合并非酒精性脂肪肝(NAFLD)的效果。方法 采用便利抽样的方法选取2022年8—12月新钢中心医院收治的T2DM合并NAFLD患者200例,根据随机数字表法分为观察组和对照组,各100例。观察组给予匹伐他汀联合利拉鲁肽治疗,对照组给予利拉鲁肽治疗,2组均治疗3个月。比较2组治疗前后血糖、血脂、肝功能、内脏脂肪指标及不良反应。结果 治疗3个月后,2组血糖、血脂及肝功能各指标均低于治疗前,且观察组低于对照组(P<0.01);2组内脏脂肪含量、趋化素、内脏脂肪素水平均低于治疗前,而网膜素水平则高于治疗前,且观察组变化幅度大于对照组(P<0.01)。观察组与对照组不良反应总发生率比较差异无统计学意义(9.00%vs. 12.00%,χ^(2)=0.479,P=0.489)。结论 匹伐他汀联合利拉鲁肽治疗T2DM合并NAFLD效果显著,能提高控糖效果,改善患者血脂及肝功能,促进内脏脂肪指标改善,且安全有保障。Objective To observe the effect of pitavastatin combined with liraglutide in the treatment of type 2 diabetes mellitus combined with non-alcoholic fatty liver disease.Methods Two hundreds patients with type 2 diabetes mellitus combined with non-alcoholic fatty liver disease admitted to XinSteel Center Hospital from August to December 2022 were selected by convenience sampling,and they were divided into observation group and control group according to random number table method,100 cases in each group.The observation group was given pitavastatin combined with liraglutide treatment,and the control group was given liraglutide treatment,both groups were treated for 3 months.The blood glucose,blood lipid,liver function,visceral fat indexes before and after treatment,and adverse reactions of the two groups were compared.Results After 3 months of treatment,the blood glucose,blood lipid and liver function indexes of the two groups were lower than before treatment,and the observation group were lower than those of the control group(P<0.01);Visceral fat content,chemokine and visceral adiponectin levels in the two groups were lower than before treatment,while retinoid level was higher than before treatment,and the magnitude of change in the observation group was greater than that in the control group(P<0.01).There was no statistically significant difference in the total incidence of adverse reactions between the observation group and control group(9.00%vs.12.00%,χ^(2)=0.479,P=0.489).Conclusion Pitavastatin combined with liraglutide in the treatment of type 2 diabetes mellitus combined with non-alcoholic fatty liver disease is effective,it can improve the effect of glycemic control,improve the patients′blood lipids and liver function,promote the improvement of the index of visceral fat,and the safety is guaranteed.

关 键 词：2型糖尿病 非酒精性脂肪肝 匹伐他汀 利拉鲁肽 肝功能 

分 类 号：R587.2[医药卫生—内分泌] R575.5[医药卫生—内科学]